Compare AbCellera Biologics Inc (ABCL) vs NetFlix Inc (NFLX) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

Netflix (NFLX) trades at $76.02, down 2.1% amid a bearish technical trend, though fundamentals remain strong with 2025 revenue of $45.18B and net income of $10.98B. The stock is near its 52-week low, with support at $75 and resistance at $77. Recent Q1 2026 earnings beat expectations with EPS of $1.23 versus $0.76 expected, highlighting robust operational performance despite market pessimism.

The outlook is mixed: strong fundamentals and a consensus price target of $114.75 suggest 51% upside, but technical weakness and competitive pressures pose risks. Investors should weigh the company's high ROE of 48.5% and scaling ad business against market sentiment and recent stock declines.